Optimizing Tableting Processes with Quality by Design - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Optimizing Tableting Processes with Quality by Design
A technical forum featuring Tim Freeman of Freeman Technology and Carl Levoguer of Malvern Instruments.

Pharmaceutical Technology
Volume 36, Issue 5, pp. 48-55

PharmTech: Can you offer any best practices for those beginning to apply a QbD approach to tableting and granulation?

Freeman (Freeman Technology): QbD relies heavily on engineering an optimized, well-understood process. It is therefore important, from the outset, to work out how to gather analytical data that will accurately reflect process performance. Effective powder handling is central to the success of tableting, granulation and a wide range of other pharmaceutical unit operations. Appropriate powder characterization techniques are, therefore, an essential prerequisite.

The number of powder testing techniques available reflects both the importance of such testing and its difficulties. When choosing which techniques to apply for QbD studies, I would suggest assessing against a number of criteria including:

  • reproducibility and sensitivity
  • process relevance
  • ease of use.

Levoguer (Malvern Instruments): One of the biggest challenges for those applying QbD is how to access and gather the necessary information. The full implementation of QbD demands a comprehensive understanding of process and product, and the identification of an effective control strategy for the manufacturing process. Choice of analytical instrumentation is therefore crucial.

With well-established techniques such as laser diffraction particle-size measurement, customers can rightly expect the highest levels of automation and analytical productivity. Some systems can extend the efficiencies of dry measurement to more samples and combine rapid measurement times with assured data quality, to push analytical productivity to high levels for all users.

Of equal importance, however, are continuous laser diffraction particle size analyzers that offer real-time measurement for pilot-scale studies and commercial plant monitoring and control. These systems can significantly accelerate QbD studies. Running a pilot plant with real-time monitoring in place enables consistent control at the experimental conditions of interest and makes the impact of changes in operating variables instantly obvious.

For some types of analysis, the technology is newer, but it is vital to recognize what can now be achieved. Returning to the example of morphologically directed imaging, these systems involve considerable investment but can deliver significant value over the long term. Being able to measure not just size and shape but also the distribution of different chemical species within a dispersed sample, such as a disintegrated tablet, can be invaluable when trying to really understand how the process works and how to optimize it.


1. X. Fu et al., Particuology 10 (2), 203–208 (2012).

2. J. Khoo et al., "Use of Surface Energy Heterogeneity to Relate the Effect of Surface Modification to Powder Properties" (Freeman Technology website, 2012), http://www.freemantech.co.uk/goto.php?link=ART_POSTER_02/, accessed Apr. 16, 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here